ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib

J. De Langen; B.C. Cho; Z. Piotrowska; X. Le; S.B. Goldberg; J.W. Goldman; I. Okamoto; N. Hewson; J. Maidment; K.H. Tang; N. Veney; J. Cosaert; J. Lau; M. Dressman; H. Ambrose; J.W. Riess; H.A. Yu

doi:10.1016/j.annonc.2022.07.1311

YUHSpace

BROWSE

0 154

Cited 0 times in

ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib

Authors: J. De Langen ; B.C. Cho ; Z. Piotrowska ; X. Le ; S.B. Goldberg ; J.W. Goldman ; I. Okamoto ; N. Hewson ; J. Maidment ; K.H. Tang ; N. Veney ; J. Cosaert ; J. Lau ; M. Dressman ; H. Ambrose ; J.W. Riess ; H.A. Yu